Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Hartford Hospital today announced in vitro results from an investigator-sponsored study that highlight delafloxacin's...

Cran-Max Effective Prevention in High Risk Cases of UTI KEARNY, NJ--(Marketwired - Oct 23, 2013) - Urinary tract infections (UTI) are responsible for more than 7 million doctor visits a year. Although UTIs can be treated in the short term with...